<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/48">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/48">
<title>The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial</title>
<dc:title>The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial</dc:title>
<dc:creator>Bhatnagar, Rahul</dc:creator>
<dc:creator>Kahan, Brennan C</dc:creator>
<dc:creator>Morley, Anna J</dc:creator>
<dc:creator>Keenan, Emma K</dc:creator>
<dc:creator>Miller, Robert F</dc:creator>
<dc:creator>Rahman, Najib M</dc:creator>
<dc:creator>Maskell, Nick A</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-015-0563-y</dc:identifier>
<dc:source>Trials 2015, 16:48</dc:source>
<dc:date>2015-02-12</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-02-12</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>48</prism:startingPage>
<prism:copyright>2015 Bhatnagar et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Rahul Bhatnagar" />
<meta name="citation_author_institution" content="Academic Respiratory Unit, University of Bristol, Southmead Hospital, Learning and Research Building, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author_institution" content="Respiratory Research, Clinical Research Centre, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author" content="Brennan C Kahan" />
<meta name="citation_author_institution" content="Pragmatic Clinical Trials Unit, Queen Mary University of London, 58 Turner Street, London E1 2AB, UK" />
<meta name="citation_author" content="Anna J Morley" />
<meta name="citation_author_institution" content="Academic Respiratory Unit, University of Bristol, Southmead Hospital, Learning and Research Building, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author_institution" content="Respiratory Research, Clinical Research Centre, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author" content="Emma K Keenan" />
<meta name="citation_author_institution" content="Academic Respiratory Unit, University of Bristol, Southmead Hospital, Learning and Research Building, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author_institution" content="Respiratory Research, Clinical Research Centre, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author" content="Robert F Miller" />
<meta name="citation_author_institution" content="Research Department of Infection and Population Health, Institute of Epidemiology and Healthcare, University College London, 222 Euston Road, London NW1 2DA, UK" />
<meta name="citation_author_institution" content="Clinical Research Department, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK" />
<meta name="citation_author" content="Najib M Rahman" />
<meta name="citation_author_institution" content="Oxford Respiratory Trials Unit, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LE, UK" />
<meta name="citation_author_institution" content="Oxford Centre for Respiratory Medicine, Churchill Hospital, Old Road, Oxford OX3 7LE, UK" />
<meta name="citation_author" content="Nick A Maskell" />
<meta name="citation_author_institution" content="Academic Respiratory Unit, University of Bristol, Southmead Hospital, Learning and Research Building, Southmead Road, Bristol BS10 5NB, UK" />
<meta name="citation_author_institution" content="Respiratory Research, Clinical Research Centre, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-02-12" />
<meta name="citation_firstpage" content="48" />
<meta name="citation_doi" content="10.1186/s13063-015-0563-y" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-015-0563-y.pdf" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-015-0563-y.pdf" />
<meta name="title" content="The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial" />
<meta name="description" content="Malignant pleural effusions (MPEs) remain a common problem, with 40,000 new cases in the United Kingdom each year and up to 250,000 in the United States. Traditional management of MPE usually involves an inpatient stay with placement of a chest drain, followed by the instillation of a pleural sclerosing agent such as talc, which aims to minimise further fluid build-up. Despite a good success rate in studies, this approach can be expensive, time-consuming and inconvenient for patients. More recently, an alternative method has become available in the form of indwelling pleural catheters (IPCs), which can be inserted and managed in an outpatient setting. It is currently unknown whether combining talc pleurodesis with IPCs will provide improved pleural symphysis rates over those of IPCs alone." />

<meta name="dc.title" content="The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial" />
<meta name="dc.creator" content="Bhatnagar, Rahul" />
<meta name="dc.creator" content="Kahan, Brennan C" />
<meta name="dc.creator" content="Morley, Anna J" />
<meta name="dc.creator" content="Keenan, Emma K" />
<meta name="dc.creator" content="Miller, Robert F" />
<meta name="dc.creator" content="Rahman, Najib M" />
<meta name="dc.creator" content="Maskell, Nick A" />
<meta name="dc.description" content="Malignant pleural effusions (MPEs) remain a common problem, with 40,000 new cases in the United Kingdom each year and up to 250,000 in the United States. Traditional management of MPE usually involves an inpatient stay with placement of a chest drain, followed by the instillation of a pleural sclerosing agent such as talc, which aims to minimise further fluid build-up. Despite a good success rate in studies, this approach can be expensive, time-consuming and inconvenient for patients. More recently, an alternative method has become available in the form of indwelling pleural catheters (IPCs), which can be inserted and managed in an outpatient setting. It is currently unknown whether combining talc pleurodesis with IPCs will provide improved pleural symphysis rates over those of IPCs alone." />
<meta name="dc.source" content="Trials 2015 16:48" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-02-12" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-015-0563-y" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Bhatnagar et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-02-12" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="48" />
<meta name="prism.copyright" content="2015 Bhatnagar et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/48/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/48" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-015-0563-y.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-015-0563-y-toc.gif" />
    
    
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/015/0563/y";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/015/0563/y</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0563/y/13407742223@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0563/y/16349502260@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/Design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li class="long">
      <a href="#sec8" class="clipped" onmouseover="outlineover(this)" onmouseout="outlineout(this)" title="Authors’ information">Authors’ info...</a>
   </li>
   <li>
      <a href="#ack">Acknowledgements</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/pdf/s13063-015-0563-y.pdf">PDF</a>
			<span>(1.5MB)</span>
		</li>

        
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                                    <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.trialsjournal.com/content/16/1/48/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22The+efficacy+of+indwelling+pleural+catheter+placement+versus+placement+plus+talc+sclerosant+in+patients+with+malignant+pleural+effusions+managed+exclusively+as+outpatients+%28IPC-PLUS%29%3A+study+protocol+for+a+randomised+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22R+Bhatnagar%22">Bhatnagar R</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22BC+Kahan%22">Kahan BC</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22AJ+Morley%22">Morley AJ</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22EK+Keenan%22">Keenan EK</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22RF+Miller%22">Miller RF</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22NM+Rahman%22">Rahman NM</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22NA+Maskell%22">Maskell NA</a>
            </li>
            </ul>          </li>
                <li>
            	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/48">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/48">on Google Scholar</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/download/xml/s13063-015-0563-y.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-015-0563-y&volume=16&issue=1&title=The+efficacy+of+indwelling+pleural+catheter+placement+versus+placement+plus+talc+sclerosant+in+patients+with+malignant+pleural+effusions+managed+exclusively+as+outpatients+%28IPC-PLUS%29%3A+study+protocol+for+a+randomised+controlled+trial&author_name=Rahul Bhatnagar&start_page=1&end_page=13">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F48" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/48', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/48" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/48', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F48" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/48', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/48" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/48', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/48', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/48" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/48" data-counturl="http://www.trialsjournal.com/content/16/1/48" data-hashtags="trials
" data-text="The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/48', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial http://www.trialsjournal.com/content/16/1/48"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/48"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0AThe%20efficacy%20of%20indwelling%20pleural%20catheter%20placement%20versus%20placement%20plus%20talc%20sclerosant%20in%20patients%20with%20malignant%20pleural%20effusions%20managed%20exclusively%20as%20outpatients%20%28IPC-PLUS%29%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F48&title=The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/48&title=The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="/content/16/1/48/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/48"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/48"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/48', 1, true]);" href="http://twitter.com/?status=The%20efficacy%20of%20indwelling%20pleural%20catheter%20placement%20versus%20placement%20plus%20talc%20sclerosant%20in%20patients%20with%20malignant%20pleural%20effusions%20managed%20exclusively%20as%20outpatients%20%28IPC-PLUS%29%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F48+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/48'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0563/y/14146779953@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0563/y/11388347538@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
					<span class="articletype">Study protocol</span>

<h1>The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																				         <strong>Rahul Bhatnagar</strong><sup><a href="/content/16/1/48/#ins1">1</a></sup><sup><a href="/content/16/1/48/#ins2">2</a></sup><sup>&#42;</sup>, <strong>Brennan C Kahan</strong><sup><a href="/content/16/1/48/#ins3">3</a></sup>, <strong>Anna J Morley</strong><sup><a href="/content/16/1/48/#ins1">1</a></sup><sup><a href="/content/16/1/48/#ins2">2</a></sup>, <strong>Emma K Keenan</strong><sup><a href="/content/16/1/48/#ins1">1</a></sup><sup><a href="/content/16/1/48/#ins2">2</a></sup>, <strong>Robert F Miller</strong><sup><a href="/content/16/1/48/#ins4">4</a></sup><sup><a href="/content/16/1/48/#ins5">5</a></sup>, <strong>Najib M Rahman</strong><sup><a href="/content/16/1/48/#ins6">6</a></sup><sup><a href="/content/16/1/48/#ins7">7</a></sup> and <strong>Nick A Maskell</strong><sup><a href="/content/16/1/48/#ins1">1</a></sup><sup><a href="/content/16/1/48/#ins2">2</a></sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                        
                                                                                                    		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Rahul  Bhatnagar <a href='mailto:Rahul.Bhatnagar@bristol.ac.uk'>Rahul.Bhatnagar@bristol.ac.uk</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                    		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                Academic Respiratory Unit, University of Bristol, Southmead Hospital, Learning and Research Building, Southmead Road, Bristol BS10 5NB, UK
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                Respiratory Research, Clinical Research Centre, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Pragmatic Clinical Trials Unit, Queen Mary University of London, 58 Turner Street, London E1 2AB, UK
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                Research Department of Infection and Population Health, Institute of Epidemiology and Healthcare, University College London, 222 Euston Road, London NW1 2DA, UK
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                Clinical Research Department, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
                            </p>
																    						    <p >
						        <sup id="ins6">6</sup>                                Oxford Centre for Respiratory Medicine, Churchill Hospital, Old Road, Oxford OX3 7LE, UK
                            </p>
																    						    <p >
						        <sup id="ins7">7</sup>                                Oxford Respiratory Trials Unit, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LE, UK
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:48&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-015-0563-y</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/48">http://www.trialsjournal.com/content/16/1/48</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>12 September 2014</td></tr>                <tr><td>Accepted:</td><td>13 January 2015</td></tr>        <tr><td>Published:</td><td>12 February 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Bhatnagar et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Malignant pleural effusions (MPEs) remain a common problem, with 40,000 new cases
         in the United Kingdom each year and up to 250,000 in the United States. Traditional
         management of MPE usually involves an inpatient stay with placement of a chest drain,
         followed by the instillation of a pleural sclerosing agent such as talc, which aims
         to minimise further fluid build-up. Despite a good success rate in studies, this approach
         can be expensive, time-consuming and inconvenient for patients. More recently, an
         alternative method has become available in the form of indwelling pleural catheters
         (IPCs), which can be inserted and managed in an outpatient setting. It is currently
         unknown whether combining talc pleurodesis with IPCs will provide improved pleural
         symphysis rates over those of IPCs alone.
      </p>
      <h4>Methods/Design</h4>
      <p style="line-height:160%">IPC-PLUS is a patient-blind, multicentre randomised controlled trial (RCT) comparing
         the combination of talc with an IPC to the use of an IPC alone for inducing pleurodesis
         in MPEs. The primary outcome is successful pleurodesis at five weeks post-randomisation.
         This study will recruit 154 patients, with an interim analysis for efficacy after
         100 patients, and aims to help to define the future gold standard for outpatient management
         of patients with symptomatic MPEs.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">IPC-PLUS is the first RCT to examine the practicality and utility of talc administered
         via an IPC. The study remains in active recruitment and has the potential to significantly
         alter how patients requiring pleurodesis for MPE are approached in the future.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">This trial was registered with Current Controlled Trials (identifier: <a href="ISRCTN73255764">ISRCTN73255764</a> <a href="http://www.webcitation.org/query.php?url=ISRCTN73255764&amp;refdoi=10.1186/s13063-015-0563-y" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>) on 23 August 2012.
      </p>
   </div>
</section><span id="keywords">
   <h5 class="inline">Keywords: </h5>Catheters; indwelling; Chest tubes; Outpatients; Pleural effusion; malignant; Pleurodesis; Sclerosing solutions; Talc; Randomised controlled trial</span><section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Malignant pleural effusions (MPEs) are a common complication of many cancers, with
         40,000 new cases in the United Kingdom each year and up to 250,000 in the United States
         <a name="d76491e227"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. Their presence usually indicates metastatic disease, and hence possibly a poorer
         prognosis.
      </p>
      <p style="line-height:160%">The traditional management of MPE involves inpatient insertion of a chest drain, to
         ensure fluid drainage and pleural apposition, before the instillation of a sclerosant
         substance to cause pleural inflammation and adhesion, also known as pleurodesis. Many
         substances can be used as a pleural irritant, although by far the most commonly used
         worldwide is talc, which has been shown to be superior to numerous alternatives <a name="d76491e233"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>].
      </p>
      <p style="line-height:160%">Quoted pleurodesis success rates are typically high with talc, ranging from 81 to
         100% <a name="d76491e239"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>], although these figures may vary considerably in real-world practice due to differences
         between clinicians and between the practices of individual centres. To achieve such
         high efficacy, a patient typically requires admission for the insertion of a chest
         tube and drainage. Only once the pleural space is felt to be dry is the talc inserted.
         This usually requires an inpatient stay of five to seven days <a name="d76491e243"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>],<a name="d76491e247"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>], which can have a significant health economic impact, as well as the potential to
         impair the quality of remaining life for patients. Following the widespread use of
         large-particle talc, the side effects of pleurodesis have tended to be minor, the
         commonest of which are fever, pain and gastrointestinal upset <a name="d76491e251"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>],<a name="d76491e255"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>],<a name="d76491e260"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>], although there have been rare cases of empyema <a name="d76491e264"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>].
      </p>
      <p style="line-height:160%">The main drawback of the traditional method of pleurodesis is the length of hospital
         stay and the inconvenience to patients. In more recent years, indwelling pleural catheters
         (IPCs) have become more widely used and may the potential to alleviate these problems.
      </p>
      <p style="line-height:160%">IPCs are silastic tubes, which have the potential to be left in place for weeks to
         months after being tunnelled under the skin. They can be inserted under local anaesthetic
         or at thoracoscopy, and are usually performed as a day case. Once at home, the aim
         is to drain fluid regularly (usually three times per week) in the patient’s own environment.
         This maximises the opportunity for pleural apposition and adhesion, which potentially
         leads to complete pleurodesis. Drainage can be performed by anyone with appropriate
         training, including the patient, but is often managed by district nursing teams.
      </p>
      <p style="line-height:160%">IPCs have been shown to be effective in the management of MPEs, although there is
         a paucity of evidence comparing them directly to talc pleurodesis. In a retrospective
         series of 250 cases, almost 90% of patients experienced complete or partial relief
         of dyspnoea <a name="d76491e274"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>], a finding bettered in a later study in which all patients experienced improvement
         <a name="d76491e278"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]. Indwelling drains have also been shown to improve other outcomes, such as length
         of hospital stay and future admissions, even in comparison to talc pleurodesis <a name="d76491e282"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>],<a name="d76491e286"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>]. Despite the need for proprietary drainage kits, they may also be cheaper overall
         to healthcare providers, if used for limited periods of time <a name="d76491e290"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>].
      </p>
      <p style="line-height:160%">Regardless of patients’ short life expectancies, this is an achievable goal as IPCs
         can often be removed following sustained reduction in drainable fluid volumes, a reliable
         surrogate indicator for pleurodesis. Such spontaneous pleurodesis generally occurs
         in around 50% of cases <a name="d76491e296"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>],<a name="d76491e300"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>],<a name="d76491e304"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>] and is heavily influenced by the underlying tumour type <a name="d76491e308"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>], although rates as high as 70% were reported in one study <a name="d76491e312"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>]. The presence of ‘trapped lung’ (usually due to central airways obstruction or visceral
         pleural fibrosis) can lead to incomplete expansion following pleural fluid drainage,
         which no doubt influenced the variability of the time to pleurodesis in these studies.
         Indeed, in patients with trapped lung, the persistent failure of pleural apposition
         makes the achievement of any degree of pleurodesis much less likely overall, meaning
         regular fluid management with an IPC may be the only feasible approach to their care.
      </p>
      <p style="line-height:160%">However, IPCs are not without drawbacks. There may be significant pain associated
         with the immediate and short-term post-procedure period, and in some cases pleural
         tract metastases have been documented <a name="d76491e318"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]. Complications including empyema formation (3%), secondary fluid loculation (12%)
         and cellulitis (2%) have also been reported <a name="d76491e322"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>]. Nevertheless, meta-analysis data has shown IPCs are generally safe to use, with
         an overall complication rate of 12.5%.
      </p>
      <p style="line-height:160%">It would seem, therefore, that the optimal approach to the management of MPEs should
         be the combination of talc instillation, to achieve the highest pleurodesis rates
         and long-term fluid prevention, and placement of an IPC to allow greater convenience
         and quality of life for the patient. This should also theoretically lead to reduced
         overall healthcare costs when compared to either individual method. Despite the potential
         for combining fluid management approached being recognised in the literature, <a name="d76491e328"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>] there have been no studies to date to test this hypothesis, although ambulatory pleurodesis
         for malignant effusions was attempted in one small series by Saffran <em>et al</em>. <a name="d76491e335"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. In this study, a closed-system pigtail catheter was inserted and pleurodesis was
         attempted at a later date using four grams of talc. Patients were managed as outpatients
         and the authors describe their method as being a viable alternative to traditional
         inpatient management. However, patient numbers were limited to 10 and there was no
         attempt at randomisation. The study took place before the widespread introduction
         of IPCs.
      </p>
      <p style="line-height:160%">The IPC-PLUS trial aims to test the hypothesis that the combination of talc in addition
         to IPCs is superior to IPCs alone in the management of MPEs. This trial has the potential
         to significantly affect, on a global scale, the way in which such effusions are managed
         in the future.
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/Design</h3>
   <div class="collapsible-content">
      <h4>Study questions</h4>
      <p style="line-height:160%">Our primary research question is, ‘In patients with a proven MPE, does the use of
         talc as a sclerosant in conjunction with an IPC increase the number of patients achieving
         successful pleurodesis, when compared to using an IPC alone?’
      </p>
      <p style="line-height:160%">Our secondary research questions are as follows:</p>
      <p style="line-height:160%">1. Does using talc and an IPC together alter the amount of pain and breathlessness
         a patient experiences, when compared to using an IPC alone?
      </p>
      <p style="line-height:160%">2. Does the use of talc and an IPC together alter a patient’s quality of life, when
         compared to using an IPC alone?
      </p>
      <p style="line-height:160%">3. What are the medical complications of using talc in conjunction with an IPC?</p>
      <p style="line-height:160%">4. What are the logistical and clinical difficulties with using talc in conjunction
         with an IPC?
      </p>
      <p style="line-height:160%">5. Does the combination of talc and an IPC together influence the degree of fluid
         septation and loculation seen on thoracic ultrasound?
      </p>
      <p style="line-height:160%">6. Does the baseline level of serum brain natriuretic peptide (BNP) correlate with
         the volume of pleural fluid drained and chance of successful pleurodesis?
      </p>
      <p style="line-height:160%">7. Does pleural elastance during initial drainage correlate with lung entrapment and
         the chance of successful pleurodesis?
      </p>
      <p style="line-height:160%">8. Is using talc in combination with IPC cost-effective when compared to IPC alone?</p>
      <h4>Sample size and power calculation</h4>
      <p style="line-height:160%">Talc pleurodesis alone has been shown to be up to 90% efficacious in trial conditions
         <a name="d76491e375"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>], and we expect the combination of talc and IPC to be at least as effective as talc
         alone. IPCs used alone have a more variable range for pleurodesis efficacy, but suggest
         an average rate of around 50%.
      </p>
      <p style="line-height:160%">Therefore, in order to detect a 25% difference in pleurodesis success at five weeks
         (using conservative estimates of 60% IPC alone versus 85% IPC and talc) with 90% power,
         a 5% significance level and 5% loss to follow-up, we would require 154 patients (77
         in each arm). An interim analysis for efficacy will take place after 100 patients
         are randomised.
      </p>
      <h4>Ethics, approvals and sponsorship</h4>
      <p style="line-height:160%">The study is sponsored in the United Kingdom by North Bristol NHS Trust, and has been
         granted the necessary (national) approvals by both the Oxford A Research Ethics Committee
         (approval number: 12/SC/0242) and the Medicines and Healthcare Products Regulatory
         Agency (MHRA) (EudraCT number: 2012-000599-40).
      </p>
      <h4>Investigational product: Novatech Steritalc®</h4>
      <p style="line-height:160%">Medicinal sterile talc as used in this trial is mined in Luzenac, France. It is marketed
         in the United Kingdom as Steritalc® and imported by GB UK Healthcare Ltd (Selby, UK).
         Talc is a naturally occurring mineral which, when processed for medical use as Steritalc,
         takes the form of a white powder of controlled particle size (graded). It is not licensed
         in the United Kingdom but is commonly used for the induction of pleurodesis, usually
         to prevent recurrence of MPEs or pneumothoraces. Medicinal talc has been licensed
         by the Food and Drug Administration (FDA) in the United States since 2003. Prior to
         introduction into the pleural cavity it is reconstituted into slurry using an inert
         solvent such as 0.9% saline. The typical dose of talc is two to four grams. Common
         side effects following pleural administration of talc are mild pleuritic pain and
         low-grade fever.
      </p>
      <h4>Study setting and design</h4>
      <p style="line-height:160%">The IPC-PLUS study is a non-commercial, patient-blind, multicentre, randomised controlled
         trial of a medicinal product. Patients will be recruited from multiple centres within
         the United Kingdom. The trial is supported by the appropriate local and regional cancer
         networks.
      </p>
      <p style="line-height:160%">Clinical care, drain insertion and imaging will be provided by local medical professionals
         at the patients’ base hospitals or appropriate satellite centres. Further care will
         be provided by ward and specialist nurses in these centres, who will also be available
         for telephone support. Routine drainage of pleural fluid will take place in the community
         and at follow-up visits. All drainages up to the 28-day post-randomisation visit will
         be performed by appropriately trained medical staff such as district nurses, lung
         cancer specialist nurses or research nurses. After this, drainages may be performed
         by anyone who has been appropriately trained (except the patient themselves).
      </p>
      <h4>Patient population</h4>
      <p style="line-height:160%">Trial patients will be recruited from those presenting with symptomatic MPEs. As part
         of their normal clinical care, it will have been decided that outpatient treatment
         with an IPC is the most appropriate strategy for fluid management.
      </p>
      <h4>Inclusion criteria</h4>
      <p style="line-height:160%">The inclusion criteria for this trial are as follows:</p>
      <p style="line-height:160%">1. Symptomatic MPE, agreed at appropriate local or regional level to require an IPC,
         defined as pleural fluid in the context of one of the following: a histocytologically
         proven pleural malignancy; an otherwise unexplained pleural effusion in the context
         of clinically proven cancer elsewhere or a radiologically proven pleural malignancy,
         as diagnosed in normal clinical practice on thoracic CT, in the absence of histocytological
         proof.
      </p>
      <p style="line-height:160%">2. Expected survival of more than two months and the Eastern Co-operative Oncology
         Group/World Health Organisation (ECOG/WHO) performance status of two or more. Patients
         with a performance status of three may be included if it is felt that removal of the
         pleural fluid would improve their performance status to two or better.
      </p>
      <p style="line-height:160%">3. Written informed consent to trial participation.</p>
      <h4>Exclusion criteria</h4>
      <p style="line-height:160%">The exclusion criteria for this trial are as follows:</p>
      <p style="line-height:160%">1. Aged under 18&nbsp;years.</p>
      <p style="line-height:160%">2. Females who are pregnant or lactating.</p>
      <p style="line-height:160%">3. Patient is unable to provide informed consent.</p>
      <p style="line-height:160%">4. Previous attempts at pleurodesis have been made within the last 56&nbsp;days on the
         same side as the effusion requiring management.
      </p>
      <p style="line-height:160%">5. Previously documented adverse reaction to talc or lidocaine.</p>
      <p style="line-height:160%">6. Community services are unable to drain the IPC at least twice per week.</p>
      <p style="line-height:160%">7. Evidence of extensive lung entrapment on a chest X-ray or computed tomography (CT)
         scan, or significant fluid loculation on an ultrasound scan, to a level which would
         normally be a contraindication to attempted talc pleurodesis or IPC insertion.
      </p>
      <p style="line-height:160%">8. Other contraindication to IPC insertion.</p>
      <p style="line-height:160%">9. Patient has no access to a telephone.</p>
      <h4>Screening and consent</h4>
      <p style="line-height:160%">Patients will be screened using the inclusion and exclusion criteria as described
         above. Screening logs documenting reasons for exclusions will be kept throughout the
         trial. Those who may be suitable for an IPC will have this option discussed in a normal
         outpatient or inpatient setting, where they will also be given the option of participating
         in the IPC-PLUS trial. Eligible patients will be invited to participate on a consecutive
         basis, and will be provided with an information leaflet at the earliest opportunity.
         They will be allowed sufficient time, as determined by the patient, to fully consider
         trial entry, as well as to ask questions of investigators. Written informed consent
         to trial participation will be obtained prior to enrolment. Consent must be taken
         by a member of the trial team and should take place before the placement of the patient’s
         IPC.
      </p>
      <h4>Trial interventions</h4>
      <p style="line-height:160%">The trial interventions are summarised in Table&nbsp;<a name="d76491e454"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/48/table/T1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/48/table/T1">1</a> and in Figure&nbsp;<a name="d76491e457"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/48/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/48/figure/F1">1</a> (trial flow chart).
         
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/48/table/T1','T1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/48/table/T1"><strong>Table 1.</strong></a> <strong>Visit schedule</strong></div>
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/48/figure/F1','F1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/48/figure/F1"><img align="top" src="/content/figures/s13063-015-0563-y-1.gif" alt="thumbnail" class="thumbnail"><strong>Figure 1.</strong></a> <strong>Summary flow chart for IPC-PLUS trial.</strong> IPC = Indwelling pleural catheter, WHO/ECOG = World Health Organisation/Eastern Cooperative
         Oncology Group, PS = Performance status, CXR = Chest X-ray, CT = Computed tomography,
         VAS = Visual analogue scale, SOB = Shortness of breath, USS = Ultrasound scan.
      </div></div>
      <h4>Pre-randomisation</h4>
      <p style="line-height:160%">Following consent, a baseline assessment will be undertaken by a member of the trial
         team and entered onto the appropriate case report form (CRF). This will include:
      </p>
      <p style="line-height:160%">1. Relevant medical history and physical examination, to include the onset and nature
         of symptoms, type of malignancy causing effusion (if known), pleural procedures to
         date, current ECOG/WHO performance status, current analgesia history and current and
         projected treatment plan outside of IPC-PLUS;
      </p>
      <p style="line-height:160%">2. Results of standard blood tests (from within 24&nbsp;hours);</p>
      <p style="line-height:160%">3. Visual-Analogue Scale (VAS) score to assess thoracic pain and breathlessness;</p>
      <p style="line-height:160%">4. Quality of life assessment using EuroQol 5D (EQ-5D) and Quality of Life Questionnaire
         C30 (QLQ-C30) health questionnaires;
      </p>
      <p style="line-height:160%">5. Chest X-ray, ideally posterior-anterior (from within previous 10&nbsp;days) and</p>
      <p style="line-height:160%">6. Thoracic ultrasound scan.</p>
      <p style="line-height:160%">Patients will then be given an appointment, if this has not already been provided,
         to have an IPC (PleurX® catheter, CareFusion, IL, USA) inserted as a day case procedure
         within one week of the baseline assessment.
      </p>
      <p style="line-height:160%">IPCs must be placed by an appropriately trained member of staff, but not necessarily
         a member of the trial team. Immediately following drain placement, a therapeutic aspiration
         should be performed. During drainage, patients should have pleural pressures measured
         after every 100 to 200 mls of fluid removed, using a calibrated electronic pleural
         manometer (Mirador Biomedical, Seattle, WA, USA). Pressure measurements should be
         recorded along with the total volume removed. A chest X-ray should be performed post-procedure
         to confirm adequate drain placement.
      </p>
      <p style="line-height:160%">Prior to discharge, the patient will be issued with a drainage booklet which will
         act as a record for the volumes of fluid drained throughout their period of trial
         participation. They will also be given a chart on which they can complete their own
         VAS scores for pain and breathlessness, which should be done on a daily basis.
      </p>
      <p style="line-height:160%">For the period post IPC insertion and before their randomisation visit, patients should
         have their fluid drained on at least five occasions, the initial drainage being immediately
         after IPC insertion prior to discharge. This first drainage may be to the maximum
         clinically appropriate volume, with subsequent drainages to a maximum of 1,000 mls
         per drainage. The patient’s fifth drainage can take place as part of their randomisation
         visit.
      </p>
      <p style="line-height:160%">Patients will attend their local trial centre 10&nbsp;days (+/− one day, as above) after
         IPC insertion. Their pleural space should be drained to dryness, or as close to dryness
         as allowed by symptoms. Following this, they should undergo a chest X-ray (ideally
         posterior-anterior) and have an appointment with a member of the trial team, who will
         perform a standardised medical assessment. Quality of life will be assessed using
         the EQ-5D and QLQ-C30 questionnaires. The chest X-ray should be examined for evidence
         of lung entrapment and significant fluid. A thoracic ultrasound of the side where
         the IPC has been inserted should be performed, looking for evidence of fluid loculation
         and septation.
      </p>
      <p style="line-height:160%">If there is evidence of significant lung entrapment (defined as &gt;25% of the hemithorax
         without expanded lung visible on a chest X-ray, as judged by two separate clinicians)
         or significant pleural fluid (defined as pleural fluid, confirmed on thoracic ultrasound,
         occupying more than one third of the hemithorax as judged by two separate clinicians
         using visual estimation on a chest X-ray), then the patient should be excluded from
         randomisation. Patients who do not meet the criteria for randomisation should have
         their on-going care devolved to the appropriate local services. Patients may also
         be excluded for other clinical reasons not relating to the degree of lung entrapment
         or residual fluid. If a patient is eligible for trial continuation at this point then
         they should be randomised at the same visit and given the allocated treatment substance
         before returning home.
      </p>
      <h4>Randomisation, blinding and emergency unblinding</h4>
      <p style="line-height:160%">Those who are eligible for will be randomly assigned in a 1:1 ratio to either receive
         intrapleural talc slurry (4&nbsp;g Novatech Steritalc mixed with 50 mls 0.9% saline) via
         the IPC, or to receive a placebo instillation of 0.9% sterile saline alone.
      </p>
      <p style="line-height:160%">Treatment allocation will be performed by an independent computer randomisation service,
         which will be accessed by the main trial coordination centre on behalf of recruitment
         centres following confirmation of suitability for randomisation. Minimisation with
         a random component will be used <a name="d76491e992"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>].
      </p>
      <p style="line-height:160%">The minimisation factors are:</p>
      <p style="line-height:160%">1. Volume of pleural fluid removed in the first 10&nbsp;days post IPC (≤1,999 mls or ≥2,000
         mls),
      </p>
      <p style="line-height:160%">2. Malignancy subtype (ovarian and breast, mesothelioma or other), and</p>
      <p style="line-height:160%">3. Day 10 chest X-ray appearance (expanded with no evidence of trapped lung or evidence
         of trapped lung but fits the criteria for randomisation).
      </p>
      <p style="line-height:160%">The study is to be performed in a single blind fashion. Patients are to be kept unaware
         of their treatment allocation, but the physician and other healthcare professionals
         involved with administering the slurry or placebo are made aware of the allocation.
         A number of methods are to be used to reduce the likelihood of a patient learning
         of their allocation. These include:
      </p>
      <p style="line-height:160%">1. Making the randomisation phone call in a separate room to the patient,</p>
      <p style="line-height:160%">2. Preparing the slurry or placebo in a separate room to the patient and ensuring
         materials are covered before the patient is brought in,
      </p>
      <p style="line-height:160%">3. Opaque syringes being used to make it less clear which substance is being administered
         and
      </p>
      <p style="line-height:160%">4. The slurry or placebo being administered from behind the patient, with the patient
         facing forward.
      </p>
      <p style="line-height:160%">Patients may have their treatment allocation revealed (unblinded) at any time according
         to clinical need. A 24-hour telephone number will be available for unblinding queries.
      </p>
      <h4>Post-randomisation</h4>
      <p style="line-height:160%">The administration of the randomised substance should be followed by an adequate flush
         to ensure as little as possible is left in the IPC line. Patients should then be observed
         for a minimum of two hours before being discharged home. Observations should include
         at least half-hourly measurements of pulse, blood pressure, temperature, pain score
         and respiratory rate. Patients must have their first post-randomisation drainage between
         12 and 36&nbsp;hours after instillation, and early communication with community nursing
         teams is vital to ensure this takes place.
      </p>
      <h4>Community drainage</h4>
      <p style="line-height:160%">Following randomisation, all patients should receive fluid drainage in the community,
         although if necessary patients may attend their local trial centre. Drainages will
         be done by an appropriately trained healthcare professional up to and including the
         day 28 follow-up visit. After this, until the end of the trial follow-up period, drainages
         may be performed by anyone with an appropriate level of training. This may include
         the patient’s family or carers, but should not be the patient themselves. The frequency
         of drainage will be at the discretion of the patient and community team, but should
         occur at least twice per week, and should begin at three times per week. Drainage
         volumes will be recorded on each occasion.
      </p>
      <h4>Clinical assessments (days 14, 28, 42, 56 and 70 post-randomisation)</h4>
      <p style="line-height:160%">The follow-up period for each patient is 10&nbsp;weeks post-randomisation, or until death.
         During this time, the first clinical assessment will occur 14&nbsp;days after randomisation,
         and at two-weekly intervals thereafter. The appointments scheduled for days 42 and
         56 may take place over the telephone. Appointments on days 14, 28 and 70 must take
         place at the base hospital or satellite centre.
      </p>
      <h4>Face-to-face appointments (mandatory on days 14, 28 and 70, optional on days 42 and
         56)
      </h4>
      <p style="line-height:160%">Before each assessment, but following arrival at the trial centre, the patient’s IPC
         should be drained to dryness by a trained member of staff. Patients should also have
         a chest X-ray (ideally posterior-anterior) after they are drained. The assessment
         should then be completed and will include:
      </p>
      <p style="line-height:160%">1. A record of any contact with medical services including hospital admissions and
         length of stay, outpatient care visit, emergency care visit and ambulance service
         use Complications of IPC placement through history and examination;
      </p>
      <p style="line-height:160%">2. Documentation of analgesia requirements (day 14 only);</p>
      <p style="line-height:160%">3. Documentation of chemotherapy and/or radiotherapy and any response;</p>
      <p style="line-height:160%">4. Current ECOG/WHO performance status;</p>
      <p style="line-height:160%">5. Quality of life assessments using EQ-5D and QLQ-C30 health questionnaires and</p>
      <p style="line-height:160%">6. A thoracic ultrasound scan, alongside completing the ultrasound CRF.</p>
      <h4>Telephone appointments (optional on days 42 and 56)</h4>
      <p style="line-height:160%">Any appointment which is to be performed over the telephone should consist of the
         following:
      </p>
      <p style="line-height:160%">1. A verbal reminder to the patient to complete and send their quality of life questionnaires
         and VAS booklets back to their local trial centre, ensuring that a VAS score is completed
         during the telephone consultation.
      </p>
      <p style="line-height:160%">2. Completion of a specific telephone follow-up CRF by the researcher, along with
         the standard health service use CRF.
      </p>
      <p style="line-height:160%">3. A review of drainage volumes with the patient over the telephone.</p>
      <p style="line-height:160%">If drainage volumes appear to have reduced to a level suggesting pleurodesis, or if
         there is any suspicion of a drainage or IPC complication, then the patient must attend
         for the next scheduled follow-up visit. Alternatively, a patient may attend the following
         day for a full face-to-face visit, with the telephone follow-up being discarded.
      </p>
      <h4>Removal of drains</h4>
      <p style="line-height:160%">Once inserted, drains may be removed at any time at the clinical discretion of the
         patient’s primary physician, at the request of the patient or at the discretion of
         the trial team. If a drain is to be removed, patients should be given an appointment
         to have this done within 14&nbsp;days of the clinical assessment at which this decision
         was taken. Any patient who has a drain removed during their post-randomisation trial
         period will continue to undergo planned follow-up for the full 70&nbsp;days.
      </p>
      <h4>Blockage of drains</h4>
      <p style="line-height:160%">All care should be taken to ensure IPCs do not become blocked, beginning with an adequate
         flush at the end of sclerosant administration. If there is a suspicion that a blockage
         has occurred then standard local unblocking procedures should be followed.
      </p>
      <h4>Biological samples and storage</h4>
      <p style="line-height:160%">During the trial baseline assessment, all patients should have standard blood tests
         for full blood count, urea and electrolytes, liver function, clotting function and
         C-reactive protein taken if there are no results available from within the previous
         24&nbsp;hours. In addition to these, at the research sites at North Bristol and Oxford,
         one ethylenediaminetetraacetic acid (EDTA), one serum gel tube and one citrate tube
         of blood should be taken. During IPC insertion, one EDTA, one serum gel tube and one
         citrate sample tube of pleural fluid should also be collected from patients at the
         North Bristol and Oxford sites. All such trial samples should be processed and stored
         as per the appropriate standard operating procedure.
      </p>
      <p style="line-height:160%">At the North Bristol and Oxford research sites, prior to each trial follow-up appointment
         (every two weeks for 10&nbsp;weeks), additional samples of pleural fluid should be collected
         during IPC drainage, before being processed and stored in the same manner as above.
      </p>
      <p style="line-height:160%">Participants will give their permission for linked anonymous blood and pleural samples
         to be stored and analysed at North Bristol NHS Trust (NBT), or, if from another site,
         for those samples to be transferred to NBT for storage and analysis. Samples will
         be stored in a dedicated freezer in the University of Bristol laboratory on the NBT
         site. Samples will be stored, anonymised and eventually destroyed in line with local
         policy.
      </p>
      <h4>Ultrasound scans</h4>
      <p style="line-height:160%">All ultrasound scans must be performed by fully trained operators (with sufficient
         experience to scan and interpret images independently) on the local research team.
         Scans will be used to assess the presence and degree of pleural fluid complexity,
         and fluid depth.
      </p>
      <h4>Visual Analogue Scale scoring</h4>
      <p style="line-height:160%">All patients will complete a VAS assessment of thoracic pain and breathlessness during
         their baseline assessment. After IPC insertion, beginning the following morning, patients
         should repeat this assessment using the documentation provided. VAS scores should
         then be recorded on a daily basis for the duration of trial involvement, with recordings
         being made each morning. If IPC drainage is due to take place that day, then the score
         should be noted before the drainage takes place.
      </p>
      <h4>End of trial</h4>
      <p style="line-height:160%">The trial will cease recruitment once the target of 154 randomised patients has been
         met, or if the Trial Steering Committee feels the interim analysis after 100 patients
         justifies early cessation. The provisional end of trial date will therefore be 10&nbsp;weeks
         after the randomisation of the final trial patient. At the end of each patient’s follow-up
         period they will be stratified as ‘alive’ or ‘dead’, and survival data collated. Further
         information regarding participants’ health status and survival may be obtained by
         accessing the NHS central register. This will require consent to be given separate
         to trial involvement. Those who still have an IPC <em>in situ</em> will have their care devolved to the appropriate local services.
      </p>
      <h4>Patient withdrawal and loss to follow-up</h4>
      <p style="line-height:160%">Patients will have originally consented to trial follow-up procedures, including sample
         collection, storage and analysis where appropriate. Patients have the right to withdraw
         from the trial at any point. A request by a patient to withdrawal does not have to
         be justified and will not affect future or on-going care. In the event of withdrawal,
         any details available regarding the reason(s) should be recorded in the patient’s
         CRF. Patients may still be stratified as ‘alive’ or ‘dead’ at the end of their follow-up
         period, unless consent for clinical data use is withdrawn. Patients who withdraw before
         randomisation will not be included in the final analysis.
      </p>
      <p style="line-height:160%">If a patient moves to an area outside of the trial centre catchment, every effort
         should be made to continue follow-up in conjunction with the new local services, or
         via the new GP. If this cannot be done, the patient will be recorded as ‘lost to follow-up’.
      </p>
      <h4>Data collection and statistical considerations</h4>
      <h4>Data collection</h4>
      <p style="line-height:160%">Data will be collected according to the schedule described above and in Table&nbsp;<a name="d76491e1128"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/48/table/T2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/48/table/T2">2</a>. Sites will enter data onto CRFs, which will be checked by the trial coordination
         centre before being entered onto an electronic database.
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/48/table/T2','T2',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/48/table/T2"><strong>Table 2.</strong></a> <strong>List of major protocol amendments</strong></div></div>
      <p style="line-height:160%">The following CRFs will be used during the trial: enrolment, baseline assessment,
         IPC insertion, day 10 assessment and randomisation, follow-up, telephone follow-up,
         thoracic ultrasound appearances, health resource utilisation and withdrawal.
      </p>
      <p style="line-height:160%">In addition to the above, patient data will also be collected via a daily patient
         VAS score booklet and a daily IPC drainage volume booklet.
      </p>
      <h4>Primary endpoint</h4>
      <p style="line-height:160%">The primary endpoint is the number of patients with successful pleurodesis at 5&nbsp;weeks
         post-randomisation. For the primary outcome measure, successful pleurodesis will be
         defined as the collection of less than, or equal to, 50 mls of pleural fluid on three
         consecutive occasions, with chest opacification on the side of the IPC less than 25%,
         as judged by two independent clinicians, who should be blind to treatment allocation.
         Information on drainage volumes will be collected in the community and during follow-up
         visits as described above. The X-ray for chest opacification must have been taken
         after the third consecutive occasion of collection of less than 50 mls of fluid, and
         within the 10-week follow-up period. All three occasions of collection of less than
         50 mls of fluid should also occur within the 10-week follow-up period.
      </p>
      <p style="line-height:160%">Patients who drain less than 50 mls of fluid on three or more occasions but who continue
         to have greater than 25% pleural opacification on a chest X-ray due to pleural fluid
         (as proven by thoracic ultrasound), will be defined as having an unsuccessful pleurodesis.
         If there is a clinical suspicion that the drain may be blocked then appropriate attempts
         to resolve this should be made prior to a definition being made.
      </p>
      <p style="line-height:160%">The achievement of pleurodesis should be dated to the first drainage of less than
         or equal to 50 mls. Even if patients achieve the requirements for pleurodesis during
         the trial period, they will continue to receive fortnightly follow-up visits as originally
         planned until the 70-day follow-up period is complete.
      </p>
      <p style="line-height:160%">Patients who die during the 10-week trial period will be assessed for whether they
         achieved pleurodesis success prior to death. This requires the collection of less
         than, or equal to, 50 mls of pleural fluid on three consecutive occasions, with chest
         opacification on the side of the IPC less than 25%, as judged by two independent clinicians,
         who should be blind to treatment allocation, with the X-ray having been taken after
         the third consecutive collection volume of less than 50 mls.
      </p>
      <h4>Secondary endpoints</h4>
      <p style="line-height:160%">The secondary endpoints for this trial are as follows:</p>
      <p style="line-height:160%">1. Self-reported quality of life status, measured at 14, 28, 42, 56 and 70&nbsp;days, using
         the EQ-5D and QLQ-C30 health questionnaires.
      </p>
      <p style="line-height:160%">2. Self-reported VAS scores, measured daily from randomisation to 10&nbsp;weeks post-randomisation,
         for thoracic pain and breathlessness.
      </p>
      <p style="line-height:160%">3. Total volume of pleural fluid drained from randomisation to 10&nbsp;weeks post-randomisation.</p>
      <p style="line-height:160%">4. All-cause mortality up to 10&nbsp;weeks post-randomisation.</p>
      <p style="line-height:160%">5. Number of hospital inpatient bed-days required from randomisation to 10&nbsp;weeks post-randomisation.</p>
      <p style="line-height:160%">6. Degree of loculation of pleural fluid following talc instillation as judged by
         thoracic ultrasound and septation score at two-weekly intervals for the 10-week follow-up
         period.
      </p>
      <p style="line-height:160%">7. Pleurodesis success at 10&nbsp;weeks post-randomisation, as defined by consecutive fluid
         volume measurement.
      </p>
      <p style="line-height:160%">8. Number of pleural procedures to relieve pleural fluid, excluding IPC drainage,
         from randomisation to up to 10&nbsp;weeks.
      </p>
      <p style="line-height:160%">9. Pleurodesis success at five and 10&nbsp;weeks post-randomisation, as defined by total
         volume of fluid collected over two consecutive weeks.
      </p>
      <p style="line-height:160%">As part of a secondary analysis, patients who have recorded drainages of less than
         or equal to a total of 250 mls of fluid over two consecutive weeks during their follow-up
         period (with appropriate radiological findings) will also be defined as having a successful
         pleurodesis. The period of two consecutive weeks may begin with any drainage which
         is undertaken during the post-randomisation trial period, and ends two weeks later
         on the same day of the week. The drainage volume recorded on this final day is included
         in the total volume for the two-week period. Patients must be drained no less frequently
         than twice per week.
      </p>
      <p style="line-height:160%">In order to be defined as having a successful pleurodesis, a patient’s chest X-ray
         must have chest opacification on the side of the IPC of less than 25%, as judged by
         two independent clinicians, who should be blind to treatment allocation. The X-ray
         for chest opacification must have been taken after the last drainage of the two-week
         period, and within the overall 10-week follow-up period.
      </p>
      <p style="line-height:160%">For patients who successfully drain less than or equal to 250 mls of fluid in a two-week
         period, the date of pleurodesis is defined as the day of the first drainage in that
         period. All drainages which count towards the total volume must occur within the study
         period.
      </p>
      <p style="line-height:160%">Patients who die during the follow-up period will also be assessed for pleurodesis
         using measurements collected prior to death. The clinical and radiological parameters
         used to define successful pleurodesis by volume over time remain the same as those
         described above.
      </p>
      <h4>Statistical analysis plan</h4>
      <p style="line-height:160%">The primary analysis will be by the intention-to-treat principle and will include
         all randomised patients on whom an outcome is available <a name="d76491e1372"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>]. All tests will be two-sided, and all analyses will be adjusted for the minimisation
         variables <a name="d76491e1376"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>]-<a name="d76491e1380"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>]. The primary outcome will be analysed using a time-to-event regression model, which
         will include mortality as a competing risk. The full statistical analysis plan for
         the IPC-PLUS trial will be written and ratified by the Trial Steering Committee prior
         to data unblinding, and will be published in a separate document.
      </p>
      <h4>Interim analysis</h4>
      <p style="line-height:160%">One interim analysis will be carried out after 100 patients are randomised in order
         to test for efficacy. The O’Brien-Fleming stopping rule will be used, which requires
         a <em>P</em> value of &lt;0.005 for the primary endpoint in order to stop the trial early <a name="d76491e1393"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a>]. If the trial is not stopped at the interim analysis, the O’Brien-Fleming rule requires
         a <em>P</em> value of &lt;0.048 at the final analysis in order to declare a statistically significant
         difference in the primary endpoint. The results of the interim analysis will be presented
         to the Independent Data Monitoring Committee, who will make a recommendation to the
         Trial Steering Committee as to whether the trial should stop early. This recommendation
         will also take into consideration other sources of evidence aside from the primary
         endpoint, such as secondary outcomes and safety data.
      </p>
      <h4>Subsidiary studies</h4>
      <p style="line-height:160%">In addition to the primary and secondary endpoints above, the trial will generate
         data to inform further sub-studies. These will relate to the trial questions which
         are not directly linked to the pleurodesis efficacy of talc, and the details of their
         analysis are beyond the scope of this protocol. Sub-studies will include the following:
      </p>
      <p style="line-height:160%">1. Examining whether the measurement of pleural elastance can be used to predict lung
         entrapment (pleural manometry).
      </p>
      <p style="line-height:160%">2. Examining whether serum levels of NT-pro BNP at baseline are related to pleurodesis
         success.
      </p>
      <p style="line-height:160%">3. Health economic analysis: the perspective adopted in the economic analysis will
         be that of the English National Health Service and Social Services. As a result we
         will collect information on the following resource use items:
      </p>
      <p style="line-height:160%">a. Intervention costs: This will entail collecting information on talc, consumables
         and staff time. This information will be obtained by reviewing hospital records. Should
         a significant between-group difference in the rates of IPC blockage and drain removal
         occur, these will also be included in the intervention cost analysis.
      </p>
      <p style="line-height:160%">b. Follow-up costs: This will entail collecting information on patients’ use of hospital
         resources after randomisation. Information collected will include inpatient stays,
         outpatient services, use of emergency departments and ambulance costs. Information
         on inpatient stays will be obtained by reviewing the administrative care records in
         each of the participating centres.
      </p>
      <h4>Trial infrastructure</h4>
      <p style="line-height:160%">The Trial Management Group is responsible for the day-to-day management of the trial.
         The team is responsible for all aspects of the project (such as recruitment rate,
         budget management, protocol adherence and so forth) and for ensuring appropriate action
         is taken to safeguard trial participants and the quality of the study. The Respiratory
         Research Unit at NBT will have responsibility for authorisation, good clinical practice
         (GCP) and conduct, data integrity, data checking and database integrity.
      </p>
      <p style="line-height:160%">The Trial Steering Committee consists of both independent members as well as researchers
         working on the trial. The role of the Trial Steering Committee is to provide overall
         supervision of the study and monitor the progress of the trial to ensure that it is
         being conducted in accordance with the protocol, relevant regulations and the principles
         of GCP. The Sponsor will be represented at Trial Steering Committee meetings but may
         choose to devolve this responsibility to a named representative.
      </p>
      <p style="line-height:160%">The Independent Data Monitoring Committee is independent of the trial investigators,
         and consists of two experienced physicians and a biostatistician. Its role is to review
         study safety data at regular intervals, and to provide advice to the Trial Steering
         Committee as to whether recruitment should continue.
      </p>
      <h4>Safety reporting</h4>
      <p style="line-height:160%">Standard definitions and medical judgement will be used for the identification of
         adverse events, adverse reactions, the expectedness and seriousness of these events
         and any potential relationship to a trial intervention. Due to the population of patients
         involved in the IPC-PLUS trial, a high number of adverse events are to be expected.
         Many of these will not be related to the investigational medicinal product administration
         or trial-related procedures, but will be as a direct consequence of the patient’s
         underlying malignancy. Other events may occur as a result of a trial-related intervention,
         but are well-documented and regarded as normal reactions in the context of talc administration.
         Expected adverse events in these settings are:
      </p>
      <p style="line-height:160%">1. Death due to underlying malignancy;</p>
      <p style="line-height:160%">2. Admission due to underlying malignancy;</p>
      <p style="line-height:160%">3. New fever after instillation of slurry or placebo (≥38°C);</p>
      <p style="line-height:160%">4. New mild tachycardia after instillation of slurry or placebo(≥20 beats per minute
         over baseline);
      </p>
      <p style="line-height:160%">5. New pleuritic chest pain after instillation of slurry or placebo, requiring simple
         analgesia (simple analgesia is defined as any medication which is not a morphine derivative
         or equivalent);
      </p>
      <p style="line-height:160%">6. New tachypnoea after instillation of slurry or placebo (increase in respiratory
         rate of five or more breaths per minute over baseline) and
      </p>
      <p style="line-height:160%">7. New hypoxia after instillation of slurry or placebo (to saturation of ≤92% on air,
         or to a level requiring additional supplemental oxygen).
      </p>
      <p style="line-height:160%">If any doubt in the causality of an event exists the local investigator should inform
         the trial coordinator who will notify the chief investigator. Pharmaceutical companies
         and/or other clinicians may be asked to advise in some cases. In the case of discrepant
         views on causality between the local investigator and others, all parties will discuss
         the case. In the event that no agreement is made, the MHRA will be informed of both
         points of view.
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The IPC-PLUS trial is a multicentre, randomised controlled trial which has the potential
         to significantly affect how patients with malignant pleural disease are treated. Although
         the TIME2 study published by Davies <em>et al</em>. suggested that first-line therapy for MPE might include IPCs <a name="d76491e1457"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>], they are currently viewed by many practitioners as predominantly a second-line treatment
         in those patients who have not had success with a talc pleurodesis.
      </p>
      <p style="line-height:160%">The combination of talc and an IPC has been used in anecdotal reports, but this is
         the first study to examine its utility in a robust way. Theoretically, the addition
         of talc to an IPC should allow for pleurodesis rates similar to that seen in bedside
         slurry to be maintained, but with the added benefit of outpatient management. This
         approach is likely to be applicable to a wide range of patients, including those with
         shorter life expectancies, those who want to minimise the duration of an IPC being
         in place or to those who have a strong preference for talc therapy but do not want
         to spend time in hospital. Given both the increasing use of IPCs worldwide and the
         availability of talc as a sclerosing agent, a positive trial outcome will likely have
         a global impact. A negative trial outcome, or if it is shown that the addition of
         talc via an IPC is detrimental to patients, would still be useful information as there
         remains a dearth of knowledge regarding this important population of patients.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">IPC-PLUS gained REC approval in May 2012 and MHRA approval in June 2012. The first
         recruitment site gained local approval in July 2012 and opened shortly after. There
         are currently 16 active recruitment sites in the United Kingdom, with a further three
         sites in the set-up phase. Recruitment will only begin at future sites once all necessary
         local approvals have been granted. As of July 2014, the study has enrolled 98 patients
         with 60 randomisations. The trial is due to complete in May 2015.
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">CRF: Case report form</p>
      <p style="line-height:160%">CT: Computed tomography</p>
      <p style="line-height:160%">ECOG/WHO: Eastern Co-operative Oncology Group/World Health Organisation</p>
      <p style="line-height:160%">EDTA: Ethylenediaminetetraacetic acid</p>
      <p style="line-height:160%">EQ-5D: EuroQol 5D health questionnaire</p>
      <p style="line-height:160%">IPC: Indwelling pleural catheter</p>
      <p style="line-height:160%">MHRA: The Medicines and Healthcare products Regulatory Agency</p>
      <p style="line-height:160%">MPE: Malignant pleural effusion</p>
      <p style="line-height:160%">NBT: North Bristol NHS Trust</p>
      <p style="line-height:160%">NHS: National Health Service</p>
      <p style="line-height:160%">NT-proBNP: N-Terminal pro-Brain Natriuretic Peptide</p>
      <p style="line-height:160%">PA: Posterior-Anterior</p>
      <p style="line-height:160%">QoL: Quality of life</p>
      <p style="line-height:160%">REC: Research Ethics Committee</p>
      <p style="line-height:160%">VAS: Visual analogue scale.</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Dr Maskell has sat on advisory board meetings, and has received unrestricted research
         funding and research consumables from CareFusion (IL, USA). Dr Rahman has acted as
         a consultant and has received research consumables from Rocket Medical (Watford, UK).
      </p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">All of the authors have made a substantial contribution to either the conception and
         design of the study, or to the acquisition of data. The manuscript was authored by
         RB, and reviewed and approved prior to final submission by BCK, AJM, EKK, RFM, NMR
         and NAM.
      </p>
   </div>
</section>
<section><a name="sec8"></a><h3>Authors’ information</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Dr Rahul Bhatnagar is the trial coordinator for IPC-PLUS. Mr Brennan Kahan is the
         lead statistician for the IPC-PLUS trial. Mrs Anna Morley is the lead trial nurse
         for IPC-PLUS. Dr Emma Keenan is the trial manager for IPC-PLUS. Prof Robert Miller
         is the Chair of the IPC-PLUS Trial Steering Committee. Dr Najib Rahman is a key investigator
         for the IPC-PLUS trial and the principal investigator for the Oxford site. Dr Nick
         Maskell is the chief investigator for the IPC-PLUS trial and is the principal investigator
         for the North Bristol site
      </p>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgements</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The authors would like to acknowledge and are grateful for the on-going contributions
         of the medical, nursing and administrative teams at all the IPC-PLUS recruitment centres.
         This study is supported by an unrestricted research grant from CareFusion, who manufacture
         the PleurX® indwelling pleural catheter. CareFusion have also supplied IPCs, drainage
         bottles and various other research consumables. There has been no commercial involvement
         in the conception, design, delivery or management of the study, the protocol, the
         statistical analysis plan or the dissemination plan.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a> Marel M,  Zrustova M,  Stasny B,  Light RW: <strong> The incidence of pleural effusion in a well-defined region: epidemiologic study in
                  central Bohemia. </strong><p><em>Chest</em> 1993,  <strong>104</strong><strong>:</strong>1486-9.  <a target="_blank" href="/pubmed/8222812">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8222812">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B1" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B1','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Shaw P,  Agarwal R: <strong> Pleurodesis for malignant pleural effusions. </strong><p><em>Cochrane Database Syst Rev</em> 2004,  <strong>1</strong><strong>:</strong>CD002916.  <a target="_blank" href="/pubmed/14973997">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14973997">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B2" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a> Roberts ME,  Neville E,  Berrisford RG,  Antunes G,  Ali NJ: Group BTSPDG: 
               	<strong> Management of a malignant pleural effusion: British Thoracic Society Pleural Disease
                  Guideline 2010. </strong><p><em>Thorax</em> 2010,  <strong>65</strong>(Suppl 2)<strong>:</strong>ii32-40.  <a target="_blank" href="/pubmed/20696691">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20696691">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B3" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Davies HE,  Mishra EK,  Kahan BC,  Wrightson JM,  Stanton AE,  Guhan A, <em>et al</em>.: <strong> Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving
                  dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled
                  trial. </strong><p><em>JAMA</em> 2012,  <strong>307</strong><strong>:</strong>2383-9.  <a target="_blank" href="/pubmed/22610520">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22610520">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Villanueva AG,  Gray AW Jr,  Shahian DM,  Williamson WA,  Beamis JF Jr: <strong> Efficacy of short term versus long term tube thoracostomy drainage before tetracycline
                  pleurodesis in the treatment of malignant pleural effusions. </strong><p><em>Thorax</em> 1994,  <strong>49</strong><strong>:</strong>23-5.  <a target="_blank" href="/pubmed/7512285">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=7512285">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Laisaar T,  Palmiste V,  Vooder T,  Umbleja T: <strong> Life expectancy of patients with malignant pleural effusion treated with video-assisted
                  thoracoscopic talc pleurodesis. </strong><p><em>Interact Cardiovasc Thorac Surg</em> 2006,  <strong>5</strong><strong>:</strong>307-10.  <a target="_blank" href="/pubmed/17670576">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17670576">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a> Viallat JR,  Rey F,  Astoul P,  Boutin C: <strong> Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. </strong><p><em>Chest</em> 1996,  <strong>110</strong><strong>:</strong>1387-93.  <a target="_blank" href="/pubmed/8989050">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8989050">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B7" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B7','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> Vargas FS,  Milanez JR,  Filomeno LT,  Fernandez A,  Jatene A,  Light RW: <strong> Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural
                  effusions. </strong><p><em>Chest</em> 1994,  <strong>106</strong><strong>:</strong>1771-5.  <a target="_blank" href="/pubmed/7988198">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=7988198">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B8" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> Tremblay A,  Michaud G: <strong> Single-center experience with 250 tunnelled pleural catheter insertions for malignant
                  pleural effusion. </strong><p><em>Chest</em> 2006,  <strong>129</strong><strong>:</strong>362-8.  <a target="_blank" href="/pubmed/16478853">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16478853">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B9" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> Warren WH,  Kalimi R,  Khodadadian LM,  Kim AW: <strong> Management of malignant pleural effusions using the Pleur(x) catheter. </strong><p><em>Ann Thorac Surg</em> 2008,  <strong>85</strong><strong>:</strong>1049-55.  <a target="_blank" href="/pubmed/18291195">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18291195">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B10" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Putnam JB Jr,  Walsh GL,  Swisher SG,  Roth JA,  Suell DM,  Vaporciyan AA, <em>et al</em>.: <strong> Outpatient management of malignant pleural effusion by a chronic indwelling pleural
                  catheter. </strong><p><em>Ann Thorac Surg</em> 2000,  <strong>69</strong><strong>:</strong>369-75.  <a target="_blank" href="/pubmed/10735665">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10735665">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B11" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Olden AM,  Holloway R: <strong> Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness
                  analysis. </strong><p><em>J Palliat Med</em> 2010,  <strong>13</strong><strong>:</strong>59-65.  <a target="_blank" href="/pubmed/19839739">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19839739">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B12" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Putnam JB Jr,  Light RW,  Rodriguez RM,  Ponn R,  Olak J,  Pollak JS, <em>et al</em>.: <strong> A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis
                  in the management of malignant pleural effusions. </strong><p><em>Cancer</em> 1999,  <strong>86</strong><strong>:</strong>1992-9.  <a target="_blank" href="/pubmed/10570423">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10570423">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Warren WH,  Kim AW,  Liptay MJ: <strong> Identification of clinical factors predicting Pleurx catheter removal in patients
                  treated for malignant pleural effusion. </strong><p><em>Eur J Cardiothorac Surg</em> 2008,  <strong>33</strong><strong>:</strong>89-94.  <a target="_blank" href="/pubmed/17983758">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17983758">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> Tremblay A,  Mason C,  Michaud G: <strong> Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. </strong><p><em>Eur Respir J</em> 2007,  <strong>30</strong><strong>:</strong>759-62.  <a target="_blank" href="/pubmed/17567670">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17567670">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B15" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Musani AI,  Haas AR,  Seijo L,  Wilby M,  Sterman DH: <strong> Outpatient management of malignant pleural effusions with small-bore, tunneled pleural
                  catheters. </strong><p><em>Respiration</em> 2004,  <strong>71</strong><strong>:</strong>559-66.  <a target="_blank" href="/pubmed/15627865">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15627865">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B16" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Pollak JS: <strong> Malignant pleural effusions: treatment with tunneled long-term drainage catheters. </strong><p><em>Curr Opin Pulm Med</em> 2002,  <strong>8</strong><strong>:</strong>302-7.  <a target="_blank" href="/pubmed/12055393">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12055393">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> Saffran L,  Ost DE,  Fein AM,  Schiff MJ: <strong> Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. </strong><p><em>Chest</em> 2000,  <strong>118</strong><strong>:</strong>417-21.  <a target="_blank" href="/pubmed/10936134">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10936134">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B18" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a> Pocock SJ,  Simon R: <strong> Sequential treatment assignment with balancing for prognostic factors in the controlled
                  clinical trial. </strong><p><em>Biometrics</em> 1975,  <strong>31</strong><strong>:</strong>103-15.  <a target="_blank" href="/pubmed/1100130">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=1100130">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B19" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B19','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a> White IR,  Horton NJ,  Carpenter J,  Pocock SJ: <strong> Strategy for intention to treat analysis in randomised trials with missing outcome
                  data. </strong><p><em>BMJ</em> 2011,  <strong>342</strong><strong>:</strong>d40.  <a target="_blank" href="/pubmed/21300711">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21300711">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B20" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Kahan BC,  Jairath V,  Dore CJ,  Morris TP: <strong> The risks and rewards of covariate adjustment in randomized trials: an assessment
                  of 12 outcomes from 8 studies. </strong><p><em>Trials</em> 2014,  <strong>15</strong><strong>:</strong>139.  <a target="_blank" href="/pubmed/24755011">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1745-6215-15-139">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Kahan BC,  Morris TP: <strong> Assessing potential sources of clustering in individually randomised trials. </strong><p><em>BMC Med Res Methodol</em> 2013,  <strong>13</strong><strong>:</strong>58.  <a target="_blank" href="/pubmed/23590245">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1471-2288-13-58">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a> Kahan BC,  Morris TP: <strong> Reporting and analysis of trials using stratified randomisation in leading medical
                  journals: review and reanalysis. </strong><p><em>BMJ</em> 2012,  <strong>345</strong><strong>:</strong>e5840.  <a target="_blank" href="/pubmed/22983531">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22983531">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B23" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B23','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a> Kahan BC,  Morris TP: <strong> Improper analysis of trials randomised using stratified blocks or minimisation. </strong><p><em>Stat Med</em> 2012,  <strong>31</strong><strong>:</strong>328-40.  <a target="_blank" href="/pubmed/22139891">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22139891">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B24" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B24','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> O’Brien PC,  Fleming TR: <strong> A multiple testing procedure for clinical trials. </strong><p><em>Biometrics</em> 1979,  <strong>35</strong><strong>:</strong>549-56.  <a target="_blank" href="/pubmed/497341">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=497341">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0563-y&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-015-0563-y&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/015/0563/y",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

